Epitopea was created by CTI and based in Montreal, Canada and Cambridge, UK. The company was founded based a novel tumor specific antigen (TSA) discovery platform from IRICoR at University of Montreal. The company is leveraging these novel TSAs and developing them into cancer vaccine against solid tumors, and exploring their use in other modalities such as TCR therapies.

Spécialité

Cancer vaccine platform

Nom du fonds

CTI LSF III

Position

Co-Lead

Conseil

Director & Observer

Date d'investissement

November 25, 2011

Détail de la sortie

Active

Ronde de la série initiale

Seed

Thèse d'investissement

Epitopea had a novel approach to identify tumor specific antigens that are highly immunogenic and shared across patients to enable true off-the-shelf cancer vaccines